Citations (25)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Ayako Yamaguchi, Shintaro Hirata, Satoshi Kubo, Shunsuke Fukuyo, Kentaro Hanami, Kazuhisa Nakano, Shingo Nakayamada, Kazuyoshi Saito & Yoshiya Tanaka. (2020) 5-year remission rate after the discontinuation of adalimumab in patients with rheumatoid arthritis: Long-term follow-up results of the HONOR study. Modern Rheumatology 30:5, pages 799-806.
Read now
Read now
MK Meyer, M Andersen, T Ring, GN Andersen, LH Ehlers, C Rasmussen & A Stensballe. (2019) Personalized rheumatic medicine through dose reduction reduces the cost of biological treatment – a retrospective intervention analysis. Scandinavian Journal of Rheumatology 48:5, pages 398-407.
Read now
Read now
Paraskevi V Voulgari & Alexandros A Drosos. (2014)
Adalimumab in the treatment of rheumatoid arthritis. Expert Opinion on Biological Therapy 14:4, pages 549-561.
Read now
Read now
Articles from other publishers (22)
Michael M. Ward, Nima Madanchi, Ali Yazdanyar, Nehal R. Shah & Florina Constantinescu. (2023) Prevalence and predictors of sustained remission/low disease activity after discontinuation of induction or maintenance treatment with tumor necrosis factor inhibitors in rheumatoid arthritis: a systematic and scoping review. Arthritis Research & Therapy 25:1.
Crossref
Crossref
Kichul Shin, Hyun Mi Kwon, Min Jung Kim, Myung Jae Yoon, Hyun Gyung Chai, Seong-Wook Kang, Won Park, Sung-Hwan Park, Chang Hee Suh, Hyun Ah Kim, Seung-Geun Lee, Choong Ki Lee, Sang-Cheol Bae, Yong-Beom Park & Yeong Wook Song. (2022) Two-year clinical outcomes after discontinuation of long-term golimumab therapy in Korean patients with rheumatoid arthritis. The Korean Journal of Internal Medicine 37:5, pages 1061-1069.
Crossref
Crossref
Lukas Schlager, Michaela Loiskandl, Daniel Aletaha & Helga Radner. (2020) Predictors of successful discontinuation of biologic and targeted synthetic DMARDs in patients with rheumatoid arthritis in remission or low disease activity: a systematic literature review. Rheumatology 59:2, pages 324-334.
Crossref
Crossref
Marjan Ghiti Moghadam, Femke B. G. Lamers-Karnebeek, Harald E. Vonkeman, Peter M. ten Klooster, Janneke Tekstra, Barbara van Schaeybroeck, Ruth Klaasen, Marieke van Onna, Hein J. Bernelot Moens, Henk Visser, Annemarie M. Schilder, Marc R. Kok, Robert B. M. Landewé, Piet L. C. M. van Riel, Mart A. F. J. van de Laar & Tim L. Jansen. (2019) Predictors of biologic-free disease control in patients with rheumatoid arthritis after stopping tumor necrosis factor inhibitor treatment. BMC Rheumatology 3:1.
Crossref
Crossref
Arduino A. Mangoni, Fahdah Al Okaily, Hani Almoallim, Seham Al Rashidi, Reem Hamdy A. Mohammed & Amal Barbary. (2019) Relapse rates after elective discontinuation of anti-TNF therapy in rheumatoid arthritis: a meta-analysis and review of literature. BMC Rheumatology 3:1.
Crossref
Crossref
Lise M Verhoef, Bart JF van den Bemt, Aatke van der Maas, Johanna E Vriezekolk, Marlies E Hulscher, Frank HJ van den Hoogen, Wilco CH Jacobs, Noortje van Herwaarden & Alfons A den Broeder. (2019) Down-titration and discontinuation strategies of tumour necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity. Cochrane Database of Systematic Reviews 2019:6.
Crossref
Crossref
Chak Sing Lau, Faith Chia, Leonila Dans, Andrew Harrison, Tsu Yi Hsieh, Rahul Jain, Seung Min Jung, Mitsumasa Kishimoto, Ashok Kumar, Khai Pang Leong, Zhanguo Li, Juan Javier Lichauco, Worawit Louthrenoo, Shue Fen Luo, Rong Mu, Peter Nash, Chin Teck Ng, Bagus Suryana, Linda Kurniaty Wijaya & Swan Sim Yeap. (2019) 2018 update of the APLAR recommendations for treatment of rheumatoid arthritis. International Journal of Rheumatic Diseases 22:3, pages 357-375.
Crossref
Crossref
Motomu Hashimoto, Moritoshi Furu, Wararu Yamamoto, Takanori Fujimura, Ryota Hara, Masaki Katayama, Akira Ohnishi, Kengo Akashi, Shuzo Yoshida, Koji Nagai, Yonsu Son, Hideki Amuro, Toru Hirano, Kosuke Ebina, Ryuji Uozumi, Hiromu Ito, Masao Tanaka, Koichiro Ohmura, Takao Fujii & Tsuneyo Mimori. (2018) Factors associated with the achievement of biological disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: the ANSWER cohort study. Arthritis Research & Therapy 20:1.
Crossref
Crossref
Marjan Ghiti Moghadam, Femke B. G. Lamers-Karnebeek, Harald E. Vonkeman, Peter M. ten Klooster, Janneke Tekstra, Annemarie M. Schilder, Henk Visser, Eric H. Sasso, David Chernoff, Willem F. Lems, Dirk-Jan van Schaardenburg, Robert Landewe, Hein J. Bernelot Moens, Timothy R. D. J. Radstake, Piet L. C. M. van Riel, Mart A. F. J. van de Laar & Tim L. Jansen. (2018) Multi-biomarker disease activity score as a predictor of disease relapse in patients with rheumatoid arthritis stopping TNF inhibitor treatment. PLOS ONE 13:5, pages e0192425.
Crossref
Crossref
Emma Simpson, Emma Hock, Matt Stevenson, Ruth Wong, Naila Dracup, Allan Wailoo, Philip Conaghan, Cristina Estrach, Christopher Edwards & Richard Wakefield. (2018) What is the added value of ultrasound joint examination for monitoring synovitis in rheumatoid arthritis and can it be used to guide treatment decisions? A systematic review and cost-effectiveness analysis. Health Technology Assessment 22:20, pages 1-258.
Crossref
Crossref
Christopher J Edwards, Bruno Fautrel, Hendrik Schulze-Koops, Tom W J Huizinga & Klaus Kruger. (2017) Dosing down with biologic therapies: a systematic review and clinicians’ perspective. Rheumatology 56:11, pages 1847-1856.
Crossref
Crossref
Lise M. Verhoef, Lieke Tweehuysen, Marlies E. Hulscher, Bruno Fautrel & Alfons A. den Broeder. (2017) bDMARD Dose Reduction in Rheumatoid Arthritis: A Narrative Review with Systematic Literature Search. Rheumatology and Therapy 4:1, pages 1-24.
Crossref
Crossref
Yoshiya Tanaka. (2016) Stopping tumour necrosis factor-targeted biological DMARDs in rheumatoid arthritis. Rheumatology 55:suppl 2, pages ii15-ii22.
Crossref
Crossref
Marjan Ghiti Moghadam, Harald E. Vonkeman, Peter M. ten Klooster, Janneke Tekstra, Dirkjan van Schaardenburg, Mirian Starmans-Kool, Elisabeth Brouwer, Reinhard Bos, Willem F. Lems, Edgar M. Colin, Cornelia F. Allaart, Inger L. Meek, Robert Landewé, Hein J. Bernelot Moens, Piet L. C. M. van Riel, Mart A. F. J. van de Laar & Tim L. Jansen. (2016) Stopping Tumor Necrosis Factor Inhibitor Treatment in Patients With Established Rheumatoid Arthritis in Remission or With Stable Low Disease Activity: A Pragmatic Multicenter, Open-Label Randomized Controlled Trial. Arthritis & Rheumatology 68:8, pages 1810-1817.
Crossref
Crossref
Raimon Sanmartí, Susana García-Rodríguez, José María Álvaro-Gracia, José Luis Andreu, Alejandro Balsa, Rafael Cáliz, Antonio Fernández-Nebro, Iván Ferraz-Amaro, Juan Jesús Gómez-Reino, Isidoro González-Álvaro, Emilio Martín-Mola, Víctor Manuel Martínez-Taboada, Ana M. Ortiz, Jesús Tornero, Sara Marsal & José Vicente Moreno-Muelas. (2015) 2014 Update of the Consensus Statement of the Spanish Society of Rheumatology on the Use of Biological Therapies in Rheumatoid Arthritis. Reumatología Clínica (English Edition) 11:5, pages 279-294.
Crossref
Crossref
Raimon Sanmart?Susana Garc?a-Rodr?guez, Jos? Mar?a ?lvaro-Gracia, Jos? Luis Andreu, Alejandro Balsa, Rafael C?liz, Antonio Fern?ndez-Nebro, Iv?n Ferraz-Amaro, Juan Jes?s G?mez-Reino, Isidoro Gonz?lez-?lvaro, Emilio Mart?n-Mola, V?ctor Manuel Mart?nez-Taboada, Ana M. Ortiz, Jes?s Tornero, Sara Marsal & Jos? Vicente Moreno-Muelas. (2015) Actualizaci?n 2014 del Documento de Consenso de la Sociedad Espa?ola de Reumatolog?a sobre el uso de terapias biol?gicas en la artritis reumatoide. Reumatolog?a Cl?nica 11:5, pages 279-294.
Crossref
Crossref
Arthur Kavanaugh, Susan J Lee, Jeffrey R Curtis, Jeffrey D Greenberg, Joel M Kremer, Lilian Soto, Carol J Etzel, Vanessa Cox, Kazuki Yoshida, George W Reed & Daniel H Solomon. (2015) Discontinuation of tumour necrosis factor inhibitors in patients with rheumatoid arthritis in low-disease activity: persistent benefits. Data from the Corrona registry. Annals of the Rheumatic Diseases 74:6, pages 1150-1155.
Crossref
Crossref
Sine Schnoor Buhl, Casper Steenholdt, Jørn Brynskov, Ole Østergaard Thomsen, Klaus Bendtzen & Mark Andrew Ainsworth. (2014) Discontinuation of infliximab therapy in patients with Crohn's disease in sustained complete remission (the STOP IT study): protocol for a double-blind, randomised, placebo-controlled, multicentre trial. BMJ Open 4:12, pages e005887.
Crossref
Crossref
Yoshiya Tanaka & Shintaro Hirata. (2014) Intensive Intervention Can Lead to a Treatment Holiday from Biological DMARDs in Patients with Rheumatoid Arthritis. Drugs 74:18, pages 2129-2139.
Crossref
Crossref
Noortje van Herwaarden, Alfons A den Broeder, Wilco Jacobs, Aatke van der Maas, Johannes WJ Bijlsma, Ronald F van Vollenhoven & Bartholomeus JF van den Bemt. (2014) Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity. Cochrane Database of Systematic Reviews.
Crossref
Crossref
Kazuki Yoshida, Yoon-Kyoung Sung, Arthur Kavanaugh, Sang-Cheol Bae, Michael E Weinblatt, Mitsumasa Kishimoto, Kazuo Matsui, Shigeto Tohma & Daniel H Solomon. (2014) Biologic discontinuation studies: a systematic review of methods. Annals of the Rheumatic Diseases 73:3, pages 595-599.
Crossref
Crossref
Iris Navarro-Millán, Sebastian E. Sattui & Jeffrey R. Curtis. (2013) Systematic Review of Tumor Necrosis Factor Inhibitor Discontinuation Studies in Rheumatoid Arthritis. Clinical Therapeutics 35:11, pages 1850-1861.e1.
Crossref
Crossref